KIR inhibitors that are being studied in clinical trials include lirilumab IPH2102 BMS 986015, Innate Pharma Bristol Myers Squibb, an anti KIR antibody, in leukemias NCT01687387, NCT02399917, NCT02481297, NCT02599649, multiple myeloma NCT02252263, and lymphoma NCT01592370; IPH2101 1 7F9, Innate Pharma in myeloma NCT01222286 and NCT01217203; and IPH4102 Innate Pharma, an anti KIR antibody that binds to three domains of the long cytoplasmic tail KIR3DL2, in lymphoma NCT02593045

مهمان عزیز شما حق دیدن لینک ها را ندارید برای استفاده از امکانات کامل انجمن عضو شوید

عضویت

Thus, as few as 4 mice per group could be used to detect a 20 difference in superficial cell density between experimental and control animals Table 1